CIC rearrangements have been reported in two-thirds of EWSR1-negative small blue round cell tumors (SBRCTs). However, a number of SBRCTs remain unclassified despite exhaustive analysis.
| I N T R O D U C T I O N
CIC-DUX4 gene fusion, resulting from either t(4;19) or t(10;19) translocation, is the most common genetic abnormality detected in EWSR1-negative small blue round cell tumors (SBRCTs).
1,2 CIC-DUX4 sarcomas occur most commonly in young adults within the somatic soft tissues. 1, [3] [4] [5] [6] Patients with CIC-rearranged sarcomas follow a clinically aggressive course, with high metastatic rate and an inferior overall survival compared with the Ewing sarcoma patients. 6, 7 Microscopically, CIC-fusion positive SBRCTs show more cytologic variability compared with classic Ewing sarcomas, with round to ovoid and occasionally spindle cell histology, showing mild nuclear pleomorphism, prominent nucleoli, and myxoid stroma. 3, 5, 6 Immunohistochemical reactivity of ETV4 has recently been reported as a useful ancillary tool in supporting the diagnosis, based on the prior evidence that CIC-DUX4 sarcomas overexpress the PEA3 subfamily of transcription factors, including ETV1, ETV4, and ETV5, both at mRNA and protein levels. 2, 4, 5, 8 RNA in situ hybridization of ETV1/4/5 was also utilized by others. 9 Another adjunct marker in diagnosing CIC-DUX4 sarcomas is the presence of nuclear immunoreactivity for WT1, which has similar sensitivity but inferior specificity compared with ETV4, being also positive in other round cell tumors, including desmoplastic small round cell tumor, alveolar rhabdomyosarcoma, Wilms tumor, lymphoblastic lymphoma, etc. 4, 5 RNA sequencing (RNAseq) has emerged as a powerful tool in identifying genetic abnormalities and has become the preferred method for novel gene fusion discovery. However, in our experience, a subset of 
| MATERIALS A ND METHODS

| Case selection
We collected 14 SBRCTs that were subjected to whole transcriptome sequencing (n 5 10) and/or targeted RNA sequencing (n 5 5, including one case tested for both platforms), but no driver genetic events were identified. Since CIC-DUX4 fusions are the most common genetic events among the EWSR1-negative SBRCTs, we further examined the RNA sequencing data for ETV1/4/5 and WT1 gene expressions, manual inspection of CIC sequences, FISH for CIC and DUX4 genetic abnormalities and immunohistochemistry for ETV4.
The patients' cohort had an equal gender distribution and a wide age range at diagnosis (11-66 years old, mean 32.8), with a bimodal distribution in the second to third and 6th to 7th decade of age. The tumors arose predominantly in soft tissues (n 5 12): 5 in the trunk, 4 in the extremities, and 3 in the head and neck, with only one case each in the phalangeal bone and brain ( [20] [21] [22] [23] Cases studied by the whole transcriptome sequencing (n 5 10)
were also subjected to unsupervised hierarchical clustering, together with > 140 samples from our database, mostly sarcomas, including 2 
| Immunohistochemistry for ETV4
Eleven of 14 cases in the study cohort with available materials were subjected for ETV4 immunostaining. Immunohistochemistry was performed on 4 mm-thick FFPE tissue sections using monoclonal mouse anti-PEA3 (ETV4) antibody (clone 16/sc-113; Santa Cruz, CA, USA;
1:50 dilution) as previously described. 4 The results were interpreted as positive when moderate or strong nuclear stain was present in at least 50% of tumor cells.
| Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR was performed in cases #2 and #8 to validate the CIC-DUX4
and DUX4-CIC fusion transcripts identified by manual inspection of RNAseq data. RNA was extracted from frozen tissues using RNeasy Plus Mini (Qiagen) and reverse transcribed by SuperScript IV FirstStrand Synthesis System (Invitrogen). PCR was performed by Advant- Additionally, 2 cases without CIC-DUX4 reads by manual inspection had instead the reciprocal DUX4-CIC fusion junction reads (cases #8,9, Table 1 , Supporting Information Table 2 ). In case # 8 the DUX4 The mRNA expression levels of ETV1, ETV4, and ETV5 in these 4 cases were markedly up-regulated compared with other tumor types ( Figure   1A , asterisks). Further WT1 stains in these 4 cases were unsuccessful, which raised the possibility of tissue failure in these samples. CD99
staining results available in 11 cases showed positivity with variable extent and intensity.
| DISCUSSION
In this study, we report a series of 14 undifferentiated round cell sarcomas that remained unclassified by RNAseq fusion discovery algorithms but surprisingly showed a distinct transcriptional ETV1/4/5 upregulation, similar to the reported mRNA signature of CIC-DUX4 sarcomas.
Upon further investigation, most cases showed some evidence of CIC-DUX4 fusions by manual inspection of RNAseq data or CIC rearrangements by FISH. DUX4 gene is located within the D4Z4 macrosatellite repeat region (11-100 copies of the repeat units) of the chromosomes 4 and 10 subtelomeric regions. 25 As the fusion discovery algorithms involve filtering out artifacts and noises, including repetitive sequences, 26 other study cohorts, 4, 5 was positive in only 64% (7/11) of our cases, which might be related to older or decalcified archival material studied.
An unusual feature of SBRCTs with CIC-DUX4 fusions is the consistent exonic DNA breakpoint for CIC, compared with the prevalent intronic DNA break seen in most other translocation-associated sarcomas. Likewise, all CIC-FOXO4 and CIC-LEUTX fusions reported to date have exonic DNA breakpoints. 24, 28, 29 Another intriguing finding is that in 2 of our cases, the CIC-DUX4 fusion resulted in a stop codon right after the fusion junction (case #6, #7 Table 2 ).
The latter fusion variant was also previously reported by our group (case #9). 1 Our findings demonstrate that cases with this fusion variant showed similar morphology and downstream effect of PEA3 family upregulation akin to other CIC-DUX4 fusions variants. The functionality of this truncation type CIC-DUX4 fusion awaits to be investigated. One hypothesis is that truncation of CIC is sufficient to induce tumorigenesis. Another possibility is that this truncation fusion variant coexists with other in-frame fusion transcripts of CIC-DUX4. The latter may be supported by the fact that the case previously reported by our group indeed had different fusion variants identified by 3 0 rapid amplification of cDNA ends (RACE). 1 All the other 9 cases reported with this fusion variant were identified by RT-PCR using the same primers. 3, 31, 32 Two of the cases showed overlapping CIC and DUX4 sequences after the presumed CIC breakpoints, which could also be explained by the presence of multiple fusion variants. 31, 32 CIC encodes a transcriptional repressor that normally inhibits The exact role in tumorigenesis of DUX4 dysregulation in the setting of CIC-DUX4 fusion remains poorly defined. DUX4 is normally expressed in testis and epigenetically silenced through CpG methylation in differentiated somatic cells. 38 Aberrant expression of DUX4 in primary human myoblasts activates genes associated with stem cell development. 39 Recently, CIC-DUX4 sarcoma has been shown to have strong DUX4 immunoexpression, while other round cell sarcomas (i.e.,
Ewing sarcoma, alveolar/embryonal rhabdomyosarcoma, synovial sarcoma, desmoplastic small round cell tumor) did not. 40 Unfortunately, our data cannot support this finding, since the DUX4 mRNA expression level cannot be evaluated in our samples due to failure of DUX4 sequence mapping.
In this study, 7 of 14 SBRCTs showed CIC-DUX4 fusion junction reads or chimeric reads upon manual inspection of RNAseq data. In 2 additional cases, only the reciprocal DUX4-CIC reads but not CIC-DUX4
were found, suggesting that in some cases, the CIC-DUX4 transcripts may not be readily amplified through the sequencing process. In fact, in some cases with CIC-DUX4 reads present, the number of wild-type CIC reads outnumbered that of CIC-DUX4 reads. The fact that CIC-DUX4 fusion transcripts are not necessarily highly expressed, at least in some cases, might explain why some cases showed CIC break-apart by FISH but no evidence of CIC alteration by manual inspection of CIC reads. reported 7 CIC-DUX4 SBRCTs identified by RT-PCR using RNA from frozen tissues. 3 The 7 samples all fell into one of the two fusion variants having different, though close, CIC breakpoints and the same DUX4 breakpoint, in contrast to the more diversely distributed breakpoints found in this study. Although the primers used in their study covered all the breakpoints we found, fusion transcripts with larger amplicons and high GC content may be difficult to amplify, as evidenced by another CIC-DUX4 SBRCT case report. 27 Since the entire study cohort showed high ETV1/4/5 expression, we further evaluated the expression of downstream targets of ETV1/4/ 5. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Among them only SPRED2, NOTCH1, and CCND2 were upregulated compared with other soft tissue tumors studied on the same RNAseq platform. SPRED2 is a negative regulator of Ras/Raf-1/ERK signaling pathway and is also up-regulated in GIST, another tumor with high ETV1 expression. NOTCH1 and CCND2 were reported as downstream targets of ETV4. 12,14 NOTCH1 signaling pathway plays an important role in embryonic development, whereas CCND2 encodes cyclin D2 that controls cell cycle progression from G1 to S phase. Both genes have been implicated in the tumorigenesis of many human cancers. [41] [42] [43] [44] In conclusion, our study demonstrates that a significant number of 
